Theseus Pharmaceuticals (THRX)

Theseus Pharmaceuticals Stock Analysis & Ratings

THRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$7.00 - $24.54
Previous Close$8.02
Average Volume (3M)64.81K
Market Cap$310.40M
P/E RatioN/A
Next EarningsMay 12, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)0.00

Theseus Pharmaceuticals News

Currently, no data available
Please return soon. This page is being updated.




P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Theseus Pharmaceuticals’s price range in the past 12 months?
Theseus Pharmaceuticals lowest stock price was $7.00 and its highest was $24.54 in the past 12 months.
    What is Theseus Pharmaceuticals’s market cap?
    Theseus Pharmaceuticals’s market cap is $310.40M.
      What is Theseus Pharmaceuticals’s price target?
      The average price target for Theseus Pharmaceuticals is $18.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $18.00 ,the lowest forecast is $18.00. The average price target represents 124.44% Increase from the current price of $8.02.
        What do analysts say about Theseus Pharmaceuticals?
        Theseus Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Theseus Pharmaceuticals’s upcoming earnings report date?
          Theseus Pharmaceuticals’s upcoming earnings report date is May 12, 2022 which is 6 days ago.
            How were Theseus Pharmaceuticals’s earnings last quarter?
            Theseus Pharmaceuticals released its earnings results on Mar 10, 2022. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.215 by -$0.025.
              Is Theseus Pharmaceuticals overvalued?
              According to Wall Street analysts Theseus Pharmaceuticals’s price is currently Undervalued.
                Does Theseus Pharmaceuticals pay dividends?
                Theseus Pharmaceuticals does not currently pay dividends.
                What is Theseus Pharmaceuticals’s EPS estimate?
                Theseus Pharmaceuticals’s EPS estimate is -$0.27.
                  How many shares outstanding does Theseus Pharmaceuticals have?
                  Theseus Pharmaceuticals has 38,700,000 shares outstanding.
                    What happened to Theseus Pharmaceuticals’s price movement after its last earnings report?
                    Theseus Pharmaceuticals reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.215. Following the earnings report the stock price went up 7.095%.
                      Which hedge fund is a major shareholder of Theseus Pharmaceuticals?
                      Among the largest hedge funds holding Theseus Pharmaceuticals’s share is Omega Fund Management, LLC. It holds Theseus Pharmaceuticals’s shares valued at 8M.


                        Theseus Pharmaceuticals Stock Analysis

                        The Theseus Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Theseus Pharmaceuticals

                        Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.

                        Similar Stocks
                        No data currently available

                        Popular Stocks

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis